Retatrutide: The Triple-Agonist Peptide and the Research Behind the Hype

Retatrutide (research designation LY3437943) is the peptide that pushed the incretin field to three receptors at once: GIP, GLP-1, and — the new addition — the glucagon receptor. Adding glucagon agonism is counterintuitive at first glance, since glucagon raises blood sugar. The rationale in the literature is that glucagon-receptor engagement can increase energy expenditure and act on hepatic lipid metabolism, while the GLP-1 component offsets the glucose effect.

What the phase 2 data showed

The pivotal report is a phase 2, double-blind, placebo-controlled trial (Jastreboff et al., 2023) in adults with obesity. At 48 weeks, least-squares mean weight change reached −22.8% at the 8 mg dose and −24.2% at 12 mg, versus −2.1% for placebo. Among participants on the higher doses, a large majority crossed the 15%-reduction threshold. These are among the largest reductions reported in a peptide obesity trial to date, which is precisely why retatrutide draws so much attention.

The liver-fat substudy

A prespecified substudy in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) reported striking reductions in liver fat: mean relative decreases exceeding 80% at the 8 and 12 mg doses at 24 weeks, with normal liver-fat content (under 5%) achieved by most participants on those doses. This positioned retatrutide as a compound of interest in liver-metabolism research, not weight alone.

Caveats researchers note

• The obesity data are phase 2 — dose-finding, not confirmatory phase 3.
• Gastrointestinal events were dose-related and mitigated by lower starting doses.
• Dose-dependent increases in heart rate were observed and are an active area of monitoring.

For research use only. This summary describes published laboratory and clinical research for educational reference. It is not medical advice and makes no claim of safety or efficacy in humans. Products are supplied strictly for in-vitro research use.